Neovascularization is involved in tumor growth as well as rheumatoid arthritis, diabetic retinopathy and age-related macular degeneration (AMD).
Neovascularization is involved in tumor growth as well as rheumatoid arthritis, diabetic retinopathy and age-related macular degeneration (AMD). 1, 2) Tumor growth is often accompanied by angiogenesis, the resulting blood vessels supplying nutrients necessary to tumor cells. The development of new blood vessels is also a crucial step in the invasion and metastases of cancer cells of breast cancer, melanoma, lung cancer, prostate cancer and other cancers.
3) Thus, discovery of drugs which suppress angiogenesis has become one of the major focuses in cancer research. Angiostatin and endostatin, which are recombinant proteins, could be such drugs, but research on low-molecular inhibitors is still being vigorously studied in pharmaceutical industry.
As part of a research program to find novel anti-angiogenic drug candidates, we synthesized 9a-fluoromedroxyprogesterone acetate (FMPA, 17a-acetoxy-9a-fluoro-6a-methylprogesterone) (1) (Fig. 1) . 4) FMPA (1) is a fluorinated analog of medroxyprogesterone acetate (MPA) (2) (Fig. 1) , which is widely used as a therapeutic agent for breast and endometrium cancer and possesses anti-angiogenic activity.
FMPA (1) exhibited an in vitro anti-angiogenic activity 100 times as strong as MPA (2) in a chorioallantoic membrane (CAM) assay system 4) and exhibited a 7-fold stronger anti-angiogenic effect than MPA in a rabbit corneal assay system. 5) In addition, FMPA (1), complexed with g-cyclodextrin (g-CyD), has shown anti-tumor effect on rat mammary carcinomas induced by 7,12-dimethylbenz[a]anthracene (DMBA) which is greater than the effect of the parent compound, MPA (2) . 5) FMPA (1) inhibits the activity of plasminogen activator (PA), an important protease playing an essential role in the process of angiogenesis, in bovine endothelial cells. 6) However, further biological evaluations such as in vitro anti-tumor tests have been difficult, because the first synthesis method of FMPA (1) developed had low overall yield (1%) and required many steps (10 steps). To overcome these problems, a practical synthetic route to FMPA (1) which involves six-steps and has 12% overall yield has been newly established. We here describe the full details of both the synthesis of FMPA (1) and its anti-tumor effect on rat mammary carcinoma when complexed with dimethyl-bcyclodextrin (DM-b-CyD).
Results and Discussion
For the synthesis of 9a-fluoro-MPA, FMPA (1), we utilized the 11b-hydroxy group of the steroid nucleus to introduce a fluorine atom at the 9a-position on both routes (Charts 1, 2). The initial route to 1 as shown in Chart 1 uses the commercially available 11b-17a-dihydroxy-4-pregnen-3,10-dione (3) as a starting material. Here, acetylation of the 11b-hydroxy group of 3 (100%) gave the compound 4. Sequential, acetalization and treatment with m-chloroperbenzoic acid (mCPBA) afforded the epoxide 6, which was reacted with CH 3 MgBr to yield the 5-hydroxy-6-methylpregnene 7. Treatment of 7 with 5% KHSO 4 followed by treatment with 0.05 N NaOH afforded the 6-methylpregnene 9 (23% yield from 4). The fluorination of the 9a-position of 9 was carried out by 70% HF in pyridine 7) to produce the 9a- fluoroprogesterone 10 (23%). The 6-methylprogesterone 10 was converted into 6a-methylprogesterone 12 by acetalization followed by deacetalization in the usual manner 8) (58% yield from 10). Finally, acetylation of 12 by the mixed anhydride method 9) provided 9a-fluoromedroxyprogesterone acetate (1) (FMPA) (36%). The overall yield of the initial synthetic route was a quite low (1%) in a ten-step sequence.
On the other hand, our improved synthesis of FMPA (1) (Chart 2) was carried out starting from 6a-methylpredonisolone 13, which is a cheaper starting material than 11b,17a-dihydroxy-4-pregnen-3,10-dione 3. Specifically, acetylation of 13 was performed with trimethylorthoacetate, and then the resulting ortho ester was hydrolyzed to give 6a-methylpredonisolone 17a-O-acetate 14 (89%). The hydroxyl group at the C-21 position of 14 was converted into the mesylate, followed by treatment with sodium iodide to yield pregnadiene-3,20-dione 15 (59%). Reduction of 15 with hydrogen atmosphere in the presence of chlorotris(triphenylphosphine)rhodium(I) 10) provided 11b-hydroxy-pregnene-3,20-dione 16 (90%). Fluorination of 16 was performed using hydrogen fluoride in pyridine to produce FMPA (1) (26%). The structure of 1 was confirmed by spectroscopy.
Thus, we succeeded in an efficient and practical synthesis of FMPA (1) with 12% overall yield in 6 steps.
FMPA (1) showed significant inhibitory effects on the growth of DMBA-induced rat mammary carcinomas at doses of 30 and 120 mg/kg as compared with a control group during the treatment and withdrawal periods (Fig. 2) . The number of tumors which appeared after treatment was also significantly inhibited by FMPA (1) doses of 30 and 120 mg/kg as compared with the control group (Fig. 3) . It has been reported that FMPA (1) complexed with g-CyD showed antitumor effect on DMBA-induced rat mammary carcinomas, and its effect is greater than that of the parent compound, MPA (2).
5) The bioavailability of FMPA (1) complexed with g-CyD was found to be about 6 times higher than that of FMPA (1) suspended in carboxymethyl cellulose sodium salt and orally administered to rats. 11) In a preliminary study of pharmacokinetics of FMPA (1) in rats, DM-b-CyD complex exhibited bioavailability about 2 times higher than g-CyD complex (unpublished data), so we used FMPA (1) complexed with DM-b-CyD in this study. As a result, FMPA (1) exhibited strong anti-tumor activity on DMBA-induced rat mammary carcinomas. Therefore, it is suggested that oral ad-ministration of FMPA (1) may be useful for treatment of mammary cancer.
Conclusions
In a preliminary work, 4) we proposed the anti-angiogenic effect of MPA (2) might be increased by giving it a fluorine atom at the C-9a position, a novel design. Based on this hypothesis, two synthetic routes of FMPA (1) were found. The newer synthetic route is a practical process using a cheaper starting material. Subsequently, potent anti-angiogenic effects have been verified for the FMPA (1) in several bioassay systems. [4] [5] [6] This study also indicates that FMPA (1) has strong anti-tumor activity, so that FMPA (1) may well be a useful oral drug for the treatment of human breast and endometrium cancer.
Experimental
General Melting points were measured on a Yanagimoto micro-melting point apparatus MP-500D and were uncorrected. Proton nuclear magnetic resonance spectra ( 1 H-NMR) were taken with a Varian Unity-500 instrument using tetramethylsilane as an internal standard. Mass spectra (MS) were determined by a Shimadzu QP5050 mass spectrometer. Elemental analysis was done by Yanaco CHN CORDER MT-6.
11b b-Acetoxy-17a a-hydroxy-4-pregnene-3,20-dione (4) A mixture of 4-pregnene-11b,17a-diol-3,20-dione 3 (2 g, 5.77 mmol), Ac 2 O (10 ml), pyridine (20 ml) and 4-dimethylaminopyridine (DMAP) (20 mg, 0.16 mmol) was stirred for 6 h at room temperature. The reaction mixture was diluted with water (50 ml) and extracted with CHCl 3 . The CHCl 3 layer was sequentially washed with 10% HCl, a 5% aqueous NaHCO 3 solution, and brine, dried over Na 2 SO 4 , and concentrated under reduced pressure. The residue was subjected to column chromatography (silica gel, 150 g) using 70% CHCl 3 /hexane as eluant to give the acetylated derivative 4 (2.24 g, 100%), mp 159.5-160°C (EtOAc/hexane). 6-Methyl-4-pregnene-11b b,17a a-diol-3,20-dione (9) 11-Acetate 4 (2 g, 5.15 mmol), ethylene glycol (1.1 g, 17.7 mmol), and p-TsOH (40 mg, 0.21 mmol) were refluxed in benzene (100 ml) for 7 h while reducing humidity (by the use of a reflux condenser equipped with a moisture separator). After the reaction temperature lowered to room temperature, the mixture was washed with brine, dried over Na 2 SO 4 , and concentrated. The residue was used directly in the next step without further purification. 70% mCPBA (2 g, 8.11 mmol) was added to the residue 5 (2 g, 4.20 mmol) in CHCl 3 (150 ml), and the mixture was stirred for 12 h at room temperature. The reaction was sequentially washed with an aqueous Na 2 CO 3 solution and brine, and then concentrated. The resultant residue 6 was thoroughly dried, and then dissolved in anhyd. THF (30 ml). While vigorously stirring the mixture, CH 3 MgBr (1.02 M THF, 30 ml, 30.6 mmol) was added. The reaction mixture was refluxed for 18 h, the temperature was lowered to room temperature, and the mixture was poured into ice-water containing NH 4 Cl. The mixture was extracted with CHCl 3 , and the organic layer was washed with saturated brine, dried over Na 2 SO 4 , and concentrated under reduced pressure. The residue 7 was refluxed at 70°C for 2 h in a mixture of acetone (80 ml) and an aqueous 5% KHSO 4 solution (40 ml). The organic layer was evaporated, and the residue was reextracted with CHCl 3 . The CHCl 3 layer was washed with saturated brine, dried over Na 2 SO 4 , and concentrated under reduced pressure. Subsequently, the residue 8 was stirred for 2 h in a mixture of 0.05 N NaOH (100 ml) and MeOH (100 ml) at room temperature. Structures of crude compounds 5-8 were supported by the detection of main signals in 1 H-NMR spectra, respectively. AcOH (1 ml) was added to the reaction mixture, and the mixture was concentrated under reduced pressure to ca. half volume. Extraction was performed with CHCl 3 . The CHCl 3 layer was washed with brine, dried over Na 2 SO 4 , and concentrated under reduced pressure. The residue was subjected to column chromatography (silica gel, 70 g) using 30% EtOAc/hexane as eluant to give the title compound 9 (23% from compound 4, mp 221-225°C (EtOAc). 9a a-Fluoro-17a a-hydroxy-6-methyl-4-pregnene-3,20-dione (10) Hydrogen fluoride-pyridine [4 ml, HF : pyridineϭ7 : 3 (w/w), 0.14 mol] was placed in a Teflon container. While maintaining the exterior temperature at Ϫ15°C, under nitrogen, 11b-hydroxy-4-pergnane-3,20-dione 9 (200 mg, 0.55 mmol) was added. The mixture was stirred for 60 h at the same temperature, and the mixture was sequentially washed with 3% HCl, 5% NaHCO 3 , and brine, dried over Na 2 SO 4 , and concentrated under reduced pressure. The residue was subjected to column chromatography (silica gel, 30 g) using 30% EtOAc/hexane as eluant to give the fluorinated compound 10 (47 mg, 23.3%), mp 232-235°C (EtOAc 9a a-Fluoro-17a a-hydroxy-6a a-methyl-4-pregnene-3,20-dione (12) The 6-methylpregnene 10 (40 mg, 0.11 mmol), ethylene glycol (0.014 ml, 0.25 mmol), and p-TsOH (2 mg, 0.01 mmol) were added to benzene (20 ml), and refluxed with heat for 3 h using a reflux condenser equipped with a moisture separator. The solvent was concentrated under reduced pressure, and the residue was combined with an aqueous 5% KHSO 4 solution (5 ml) and acetone (5 ml). The mixture was refluxed for 2 h at 70°C. The reaction mixture was concentrated under reduced pressure, and then the residue was extracted with CHCl 3 . The CHCl 3 layer was washed with saturated brine, dried over Na 2 SO 4 , and concentrated under reduced pressure. The residue was subjected to column chromatography (silica gel, 20 g) using 30% EtOAc/hexane as eluant to give the methylated derivative 12 (23 mg, 57.5% from compound 10), mp 237-239°C (EtOAc 17a a-Acetoxy-9a a-fluoro-6a a-methylprogesterone (1) 9a-Fluoromedroxyprogesterone 12 (20 mg, 0.055 mmol) was stirred for 5 h at Ϫ10°C in the presence of p-TsOH (20 mg, 0.11 mmol), Ac 2 O (0.4 ml, 4.23 mmol), and CH 2 Cl 2 (1 ml) under nitrogen. Water (10 ml) was added to the reaction mixture, and extraction was performed with CHCl 3 . The CHCl 3 layer was washed with an aqueous 5% NaHCO 3 solution and saturated brine, dried over Na 2 SO 4 , and concentrated under reduced pressure. The residue was subjected to column chromatography (silica gel, 20 g) using 30% EtOAc/hexane as eluant to give the 17a-acetoxy-9a-fluoro-6a-methylprogesterone (1) 17a a -Acetoxy-11b b ,21-dihydroxy-6a a -methyl-1,4-pregnadiene-3,20-dione (14) Pyridinium p-toluenesulfonate (28.0 mg, 0.11 mmol) and trimethyl orthoacetate (1.01 ml, 7.94 mmol) were added to a solution (60 ml) of 6a-methylpredonisolone (6a-methyl-11b,17a,21-trihydroxy-1,4-pregnadiene-3,20-dione) 13 (2.13 g, 5.69 mmol) in CH 2 Cl 2 . The mixture was stirred at room temperature (20-25°C) for 5 h. When the reaction was completed, the reaction mixture was concentrated under reduced pressure. The residue was dissolved in acetone (30 ml). While cooling the mixture on ice, an aqueous solution (30 ml) of p-TsOH (1.19 g, 6.26 mmol) was added thereto. The mixture was stirred for 30 min on ice. Upon completion of reaction, a saturated aqueous NaHCO 3 solution was added and extraction was performed with EtOAc. The EtOAc layer was washed with brine, dried over Na 2 SO 4 , and concentrated under reduced pressure. The residue was purified by column chromatography (silica gel, 40 g) using 50% EtOAc/hexane as eluant to give 17a-acetoxy-11b,21-dihydroxy-6a-methyl-1,4-pregnadiene-3,20-dione 14 (2.11 g, 89%), mp 159-161°C (EtOAc 17a a-Acetoxy-11b b-hydroxy-6a a-methyl-1,4-pregnadiene-3,20-dione (15) Methanesulfonyl chloride (MsCl) (0.15 ml, 1.94 mmol) was added to a solution of 17a-acetoxy-11b,21-dihydroxy-6a-methyl-1,4-pregnadiene-3,20-dione 14 (557 mg, 1.34 mmol) in pyridine (10 ml). The mixture was stirred at between 0 and 5°C (external temperature) for 3 h. After completion of reaction, iced water and ethyl acetate were added to the reaction mixture. The resultant mixture was sequentially washed with 10% HCl, a saturated aqueous NaHCO 3 solution, and brine, and then dried over Na 2 SO 4 . After the sol0vent was evaporated under reduced pressure, the residue was dissolved in pyridine (10 ml). Sodium iodide (447 mg, 2.98 mmol) was added to the solution, and the mixture was refluxed for 50 min. Upon completion of the reaction, a saturated aqueous Na 2 SO 3 solution was added to the reaction mixture, and then extraction was performed with EtOAc. The EtOAc layer was washed with 10% HCl, a saturated aqueous NaHCO 3 solution, saturated brine, and dried over Na 2 SO 4 . The organic layer was evaporated under reduced pressure. The residue was subjected to silica gel column chromatography (silica gel, 16 g) using 50% EtOAc/hexane as eluant to give 17a-acetoxy-11b-hydroxy-6a-methyl-1,4-pregnadiene-3,20-dione 15 (316 mg, 59%), mp 138-140°C (EtOAc 17a a-Acetoxy-11b b-hydroxy-6a a-methyl-4-pregnene-3,20-dione (16) Chlorotris(triphenylphosphine)rhodium(I) (8.51 mg, 9.20 mmol) was added to a solution of 17a-acetoxy-11b-hydroxy-6a-methyl-1,4-pregnadiene-3,20-dione 15 (316 mg, 0.79 mmol) in CH 2 Cl 2 -EtOH (1 : 1; 30 ml). The mixture was stirred for 27 h at room temperature (20-25°C) in a stream of hydrogen gas (1.5 kg/cm 2 ). After completion of reaction, the reaction mixture was concentrated under reduced pressure. The residue was subjected to silica gel column chromatography (silica gel, 10 g) using 50% EtOAc/hexane as eluant to give 17a-acetoxy-11b-hydroxy-6a-methyl-4-pregnene-3,20-dione 16 (285 mg, 90%) 17a a-Acetoxy-9a a-fluoro-6a a-methylprogesterone (1) Hydrogen fluoride-pyridine [4 ml, HF : pyridineϭ7 : 3 (w/w), 0.14 mol] was placed in a Teflon container. While maintaining the exterior temperature at Ϫ15°C, under nitrogen, 17a-acetoxy-11b-hydroxy-6a-methyl-4-pregnene-3,20-dione 16 (145 mg, 0.36 mmol) was added. The solution was stirred for 65 h at the same external temperature of Ϫ15°C. When the reaction was completed, ice water was added to the reaction mixture, which was then extracted with EtOAc (50 ml, 30 ml). The organic layer was sequentially washed with 10% HCl, saturated NaHCO 3 , and brine, and then dried over Na 2 SO 4 . After the solvent was evaporated under reduced pressure, the residue was subjected to column chromatography (silica gel, 6 g) using 40% EtOAc/hexane as eluant to give 17a-acetoxy-9a-fluoro-6a-methylprogesterone (1) (37.9 mg, 26%), which was identical with the FMPA synthesized previously in all respects.
Anti-tumor Effect on Rat Mammary Carcinoma The following animal studies were performed in accordance with the Guiding Principles for the Care and Use of Laboratory Animals approved by the Japanese Pharmacological Society. DMBA was administered orally at a single dose of 20 mg/body to female Sprague-Dawley rats about 50 days old. When the diameter of the first developed mammary tumor became 0.5-1.5 cm 8-12 weeks after DMBA administration, the animal was incorporated into the study. FMPA (1), complexed with DM-b-CyD, was administered to the animals orally once a day at doses of 30 and 120 mg/kg/day for 3 weeks. Distilled water and DM-b-CyD (498 mg/ml) were administered to the animals orally once a day at a volume of 6 ml/kg/day for 3 weeks. The two largest perpendicular diameters of each tumor were measured on the first day of treatment and thereafter once a week for 6 weeks. The multiplied product of these diameters was expressed as tumor size. Number of tumors per rat appeared after treatment was also counted.
